NewsOK member benefits
Web Search powered by YAHOO!
Published: August 28, 2008
Business Briefs
NATION
Genentech stands still on blindness treatments
WASHINGTON — What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc. , nothing.
The company declined to seek federal approval for the cheaper drug, Avastin , to...
You have selected to view an article that is older than 60 days. Get access to all our historical content by purchasing a pass to The Oklahoman. Select the option that works best for you.
Archive Subscription types & rates
